A review of human vaccine research and development: Malaria

Vaccine

Volumn 25, Issue 9, 2007, Pages 1567-1580

  Girard, Marc P ^a   Reed, Zarifah H ^b   Friede, Martin ^b   Kieny, Marie Paule ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Africa; Clinical trials; Merozoites; Plasmodium; Sporozoites; Vaccine

Indexed keywords

APICAL MEMBRANE ANTIGEN 1; CIRCUMSPOROZOITE PROTEIN; DNA VACCINE; EXPORTED PROTEIN 1; GLUTAMATE RICH PROTEIN; IMMUNOLOGICAL ADJUVANT; LIVER STAGE ANTIGEN 1; LIVER STAGE ANTIGEN 3; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 2; MEROZOITE SURFACE PROTEIN 3; MEROZOITE SURFACE PROTEIN 4; MEROZOITE SURFACE PROTEIN 5; MEROZOITE SURFACE PROTEIN 8; MEROZOITE SURFACE PROTEIN 9; MODIFIED VACCINIA ANKARA VACCINE; MUSTDO 5 VACCINE; PFCP 2.9 VACCINE; PFEBA 175 ANTIGEN; RECOMBINANT VACCINE; RING STAGE INFECTED ERYTHROCYTE SURFACE ANTIGEN; RTS,S AS02 VACCINE; RTS,S VACCINE; SERINE REPEAT ANTIGEN; SPF66 VACCINE; SPOROZOITE AND LIVER STAGE ANTIGEN; SPOROZOITE SURFACE PROTEIN 2; SPOROZOITE THREONINE AND ASPARAGINE RICH PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADJUVANT THERAPY; ANTIGEN PURIFICATION; ASEXUAL REPRODUCTION; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ERYTHROCYTE; GENOME; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; MALARIA; MEROZOITE; NONHUMAN; PARASITE VECTOR; PARASITOLOGY; PLASMODIUM; PLASMODIUM FALCIPARUM; PLASMODIUM MALARIAE; PLASMODIUM OVALE; PLASMODIUM VIVAX; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SPOROZOITE; VACCINE PRODUCTION;

ANIMALS; ANTIGENS, PROTOZOAN; DRUG DESIGN; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; RESEARCH;

EID: 33846256606     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.09.074     Document Type: Review

References (166)

1. World Malaria Report. World Health Organization, 2005.
2. Subbarao S.K., and Sharma V.P. Anopheline species complexes & malaria control. Indian J Med Res 106 (1997) 164-173
3. Riehle M.M., Markianos K., Niare O., Xu J., Li J., Toure A.M., et al. Natural malaria infection in Anopheles gambiae is regulated by a single genomic control region. Science 312 5773 (2006) 577-579
4. Dubovsky F., and Rabinovich N.R. Malaria vaccines. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines. 4th ed. (2004), Saunders, Philadelphia 1283-1289
5. Miller L.H., Baruch D.I., Marsh K., and Doumbo O.K. The pathogenic basis of malaria. Nature 415 6872 (2002) 673-679
6. Greenwood B. Malaria vaccines. Evaluation and implementation. Acta Trop 95 3 (2005) 298-304
7. Ro D.K., Paradise E.M., Ouellet M., Fisher K.J., Newman K.L., Ndungu J.M., et al. Production of the antimalarial drug precursor artemisinic acid in engineered yeast. Nature 440 7086 (2006) 940-943
8. Malkin E., Dubovsky F., and Moree M. Progress towards the development of malaria vaccines. Trends Parasitol 22 7 (2006) 292-295
9. Day K.P., and Marsh K. Naturally acquired immunity to Plasmodium falciparum. Immunol Today 12 3 (1991) A68-A71
10. Smith T.A., Leuenberger R., and Lengeler C. Child mortality and malaria transmission intensity in Africa. Trends Parasitol 17 3 (2001) 145-149
11. Sabchareon A., Burnouf T., Ouattara D., Attanath P., Bouharoun-Tayoun H., Chantavanich P., et al. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg 45 3 (1991) 297-308
12. Nussenzweig R.S., Vanderberg J., Most H., and Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature 216 111 (1967) 160-162
13. Alonso P.L., Sacarlal J., Aponte J.J., Leach A., Macete E., Milman J., et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364 9443 (2004) 1411-1420
14. Smith P.G., and Milligan P.J. Malaria vaccine: 3 or 6 months' protection?. Lancet 365 9458 (2005) 472-473
15. Targett G.A. Malaria vaccines 1985-2005: a full circle?. Trends Parasitol 21 11 (2005) 499-503
16. Aguiar J.C., LaBaer J., Blair P.L., Shamailova V.Y., Koundinya M., Russell J.A., et al. High-throughput generation of P. falciparum functional molecules by recombinational cloning. Genome Res 14 10B (2004) 2076-2082
17. Duffy P.E., Krzych U., Francis S., and Fried M. Malaria vaccines: using models of immunity and functional genomics tools to accelerate the development of vaccines against Plasmodium falciparum. Vaccine 23 17/18 (2005) 2235-2242
18. Reed Z.H., Friede M., and Kieny M.P. Malaria vaccine development: progress and challenges. Curr Mol Med 6 2 (2006) 231-245
19. Kemp D.J., Coppel R.L., Cowman A.F., Saint R.B., Brown G.V., and Anders R.F. Expression of Plasmodium falciparum blood-stage antigens in Escherichia coli: detection with antibodies from immune humans. Proc Natl Acad Sci USA 80 12 (1983) 3787-3791
20. Ellis J., Ozaki L.S., Gwadz R.W., Cochrane A.H., Nussenzweig V., Nussenzweig R.S., et al. Cloning and expression in E. coli of the malarial sporozoite surface antigen gene from Plasmodium knowlesi. Nature 302 5908 (1983) 536-538
21. Good M.F. Vaccine-induced immunity to malaria parasites and the need for novel strategies. Trends Parasitol 21 1 (2005) 29-34
22. Good M.F., Kaslow D.C., and Miller L.H. Pathways and strategies for developing a malaria blood-stage vaccine. Annu Rev Immunol 16 (1998) 57-87
23. Makobongo M.O., Keegan B., Long C.A., and Miller L.H. Immunization of Aotus monkeys with recombinant cysteine-rich interdomain region 1 alpha protects against severe disease during Plasmodium falciparum reinfection. J Infect Dis 193 5 (2006) 731-740
24. Sabatinelli G., Ejov M., and Joergensen P. Malaria in the WHO European Region (1971-1999). Euro Surveill 6 4 (2001) 61-65
25. Sunstrum J., Elliott L.J., Barat L.M., Walker E.D., and Zucker J.R. Probable autochthonous Plasmodium vivax malaria transmission in Michigan: case report and epidemiological investigation. Am J Trop Med Hyg 65 6 (2001) 949-953
26. Kovats R.S., Bouma M.J., Hajat S., Worrall E., and Haines A. El Nino and health. Lancet 362 9394 (2003) 1481-1489
27. Lindsay S.W., and Martens W.J. Malaria in the African highlands: past, present and future. Bull World Health Organ 76 1 (1998) 33-45
28. Maguire J.D., Tuti S., Sismadi P., Wiady I., Basri H., Krisin, et al. Endemic coastal malaria in the Thousand Islands District, near Jakarta, Indonesia. Trop Med Int Health 10 5 (2005) 489-496
29. Chen Q., Schlichtherle M., and Wahlgren M. Molecular aspects of severe malaria. Clin Microbiol Rev 13 3 (2000) 439-450
30. Murphy S.C., and Breman J.G. Gaps in the childhood malaria burden in Africa: cerebral malaria, neurological sequelae, anemia, respiratory distress, hypoglycemia, and complications of pregnancy. Am J Trop Med Hyg 64 1/2 Suppl (2001) 57-67
31. Guinovart C., Navia M.M., Tanner M., and Alonso P.L. Malaria: burden of disease. Curr Mol Med 6 2 (2006) 137-140
32. Gallup J.L., and Sachs J.D. The economic burden of malaria. Am J Trop Med Hyg 64 1/2 Suppl (2001) 85-96
33. Sachs J., and Malaney P. The economic and social burden of malaria. Nature 415 6872 (2002) 680-685
34. Tuikue Ndam N.G., Salanti A., Le-Hesran J.Y., Cottrell G., Fievet N., Turner L., et al. Dynamics of anti-VAR2CSA immunoglobulin G response in a cohort of senegalese pregnant women. J Infect Dis 193 5 (2006) 713-720
35. Fried M., Domingo G.J., Gowda C.D., Mutabingwa T.K., and Duffy P.E. Plasmodium falciparum: chondroitin sulfate A is the major receptor for adhesion of parasitized erythrocytes in the placenta. Exp Parasitol 113 1 (2006) 36-42
36. Egan J.E., Hoffman S.L., Haynes J.D., Sadoff J.C., Schneider I., Grau G.E., et al. Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Am J Trop Med Hyg 49 2 (1993) 166-173
37. Hoffman S.L., Goh L.M., Luke T.C., Schneider I., Le T.P., Doolan D.L., et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 185 8 (2002) 1155-1164
38. Trape J.F., Rogier C., Konate L., Diagne N., Bouganali H., Canque B., et al. The Dielmo project: a longitudinal study of natural malaria infection and the mechanisms of protective immunity in a community living in a holoendemic area of Senegal. Am J Trop Med Hyg 51 2 (1994) 123-137
39. Baird J.K. Age-dependent characteristics of protection vs. susceptibility to Plasmodium falciparum. Ann Trop Med Parasitol 92 4 (1998) 367-390
40. Hill A.V. Pre-erythrocytic malaria vaccines: towards greater efficacy. Nat Rev Immunol 6 1 (2006) 21-32
41. Luke T.C., and Hoffman S.L. Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J Exp Biol 206 Pt 21 (2003) 3803-3808
42. Mueller A.K., Labaied M., Kappe S.H., and Matuschewski K. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 433 7022 (2005) 164-167
43. van Dijk M.R., Douradinha B., Franke-Fayard B., Heussler V., van Dooren M.W., van Schaijk B., et al. Genetically attenuated, P36p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells. Proc Natl Acad Sci USA 102 34 (2005) 12194-12199
44. Walther M. Advances in vaccine development against the pre-erythrocytic stage of Plasmodium falciparum malaria. Expert Rev Vaccines 5 1 (2006) 81-93
45. Doolan D.L., and Hoffman S.L. The complexity of protective immunity against liver-stage malaria. J Immunol 165 3 (2000) 1453-1462
46. Nardin E.H., and Nussenzweig R.S. T cell responses to pre-erythrocytic stages of malaria: role in protection and vaccine development against pre-erythrocytic stages. Annu Rev Immunol 11 (1993) 687-727
47. Tsuji M., Mombaerts P., Lefrancois L., Nussenzweig R.S., Zavala F., and Tonegawa S. Gamma delta T cells contribute to immunity against the liver stages of malaria in alpha beta T-cell-deficient mice. Proc Natl Acad Sci USA 91 1 (1994) 345-349
48. Good M.F., and Doolan D.L. Immune effector mechanisms in malaria. Curr Opin Immunol 11 4 (1999) 412-419
49. Nardin E., Zavala F., Nussenzweig V., and Nussenzweig R.S. Pre-erythrocytic malaria vaccine: mechanisms of protective immunity and human vaccine trials. Parassitologia 41 1-3 (1999) 397-402
50. Gonzalez-Aseguinolaza G., de Oliveira C., Tomaska M., Hong S., Bruna-Romero O., Nakayama T., et al. Alpha-galactosylceramide-activated Valpha 14 natural killer T cells mediate protection against murine malaria. Proc Natl Acad Sci USA 97 15 (2000) 8461-8466
51. Sun P., Schwenk R., White K., Stoute J.A., Cohen J., Ballou W.R., et al. Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma. J Immunol 171 12 (2003) 6961-6967
52. Stoute J.A., Slaoui M., Heppner D.G., Momin P., Kester K.E., Desmons P., et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 336 2 (1997) 86-91
53. Kester K.E., McKinney D.A., Tornieporth N., Ockenhouse C.F., Heppner D.G., Hall T., et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis 183 4 (2001) 640-647
54. Stoute J.A., Kester K.E., Krzych U., Wellde B.T., Hall T., White K., et al. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J Infect Dis 178 4 (1998) 1139-1144
55. Bojang K.A., Milligan P.J., Pinder M., Vigneron L., Alloueche A., Kester K.E., et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358 9297 (2001) 1927-1934
56. Bojang K.A., Olodude F., Pinder M., Ofori-Anyinam O., Vigneron L., Fitzpatrick S., et al. Safety and immunogenicity of RTS,S/AS02A candidate malaria vaccine in Gambian children. Vaccine 23 32 (2005) 4148-4157
57. Alonso P.L., Sacarlal J., Aponte J.J., Leach A., Macete E., Aide P., et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366 9502 (2005) 2012-2018
58. Heppner Jr. D.G., Kester K.E., Ockenhouse C.F., Tornieporth N., Ofori O., Lyon J.A., et al. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine 23 17/18 (2005) 2243-2250
59. Alonso P.L. Malaria: deploying a candidate vaccine (RTS,S/AS02A) for an old scourge of humankind. Int Microbiol 9 2 (2006) 83-93
60. Dunachie S.J., Walther M., Vuola J.M., Webster D.P., Keating S.M., Berthoud T., et al. A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. Vaccine 24 15 (2006) 2850-2859
61. Roggero M.A., Filippi B., Church P., Hoffman S.L., Blum-Tirouvanziam U., Lopez J.A., et al. Synthesis and immunological characterization of 104-mer and 102-mer peptides corresponding to the N- and C-terminal regions of the Plasmodium falciparum CS protein. Mol Immunol 32 17/18 (1995) 1301-1309
62. Prato S., Maxwell T., Pinzon-Charry A., Schmidt C.W., Corradin G., and Lopez J.A. MHC class I-restricted exogenous presentation of a synthetic 102-mer malaria vaccine polypeptide. Eur J Immunol 35 3 (2005) 681-689
63. Nardin E.H., Oliveira G.A., Calvo-Calle J.M., Castro Z.R., Nussenzweig R.S., Schmeckpeper B., et al. Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes. J Infect Dis 182 5 (2000) 1486-1496
64. Kublin J.G., Lowitt M.H., Hamilton R.G., Oliveira G.A., Nardin E.H., Nussenzweig R.S., et al. Delayed-type hypersensitivity in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites. Vaccine 20 13/14 (2002) 1853-1861
65. Walther M., Dunachie S., Keating S., Vuola J.M., Berthoud T., Schmidt A., et al. Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. Vaccine 23 7 (2005) 857-864
66. Imoukhuede E.B., Berthoud T., Milligan P., Bojang K., Ismaili J., Keating S., et al. Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men. Vaccine (2006)
67. Matuschewski K. Vaccine development against malaria. Curr Opin Immunol 18 4 (2006) 449-457
68. Walther M., Thompson F.M., Dunachie S., Keating S., Todryk S., Berthoud T., et al. Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein. Infect Immun 74 5 (2006) 2706-2716
69. Bejon P., Peshu N., Gilbert S.C., Lowe B.S., Molyneux C.S., Forsdyke J., et al. Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya. Clin Infect Dis 42 8 (2006) 1102-1110
70. Webster D.P., Dunachie S., McConkey S., Poulton I., Moore A.C., Walther M., et al. Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 24 15 (2006) 3026-3034
71. Le T.P., Coonan K.M., Hedstrom R.C., Charoenvit Y., Sedegah M., Epstein J.E., et al. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 18 18 (2000) 1893-1901
72. Parker S.E., Monteith D., Horton H., Hof R., Hernandez P., Vilalta A., et al. Safety of a GM-CSF adjuvant-plasmid DNA malaria vaccine. Gene Ther 8 13 (2001) 1011-1023
73. Wang R., Doolan D.L., Le T.P., Hedstrom R.C., Coonan K.M., Charoenvit Y., et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282 5388 (1998) 476-480
74. Wang R., Epstein J., Baraceros F.M., Gorak E.J., Charoenvit Y., Carucci D.J., et al. Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. Proc Natl Acad Sci USA 98 19 (2001) 10817-10822
75. Moore A.C., and Hill A.V. Progress in DNA-based heterologous prime-boost immunization strategies for malaria. Immunol Rev 199 (2004) 126-143
76. Hill A.V., Reece W., Gothard P., Moorthy V., Roberts M., Flanagan K., et al. DNA-based vaccines for malaria: a heterologous prime-boost immunisation strategy. Dev Biol (Basel) 104 (2000) 171-179
77. Moorthy V.S., Imoukhuede E.B., Milligan P., Bojang K., Keating S., Kaye P., et al. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med 1 2 (2004) e33
78. Dunachie S.J., Walther M., Epstein J.E., Keating S., Berthoud T., Andrews L., et al. A DNA prime-modified vaccinia virus Ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect Immun 74 10 (2006) 5933-5942
79. Webster D.P., Dunachie S., Vuola J.M., Berthoud T., Keating S., Laidlaw S.M., et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci USA 102 13 (2005) 4836-4841
80. Bejon P., Mwacharo J., Kai O.K., Todryk S., Keating S., Lang T., et al. Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area. Vaccine 24 22 (2006) 4709-4715
81. Benmohamed L., Thomas A., Bossus M., Brahimi K., Wubben J., Gras-Masse H., et al. High immunogenicity in chimpanzees of peptides and lipopeptides derived from four new Plasmodium falciparum pre-erythrocytic molecules. Vaccine 18 25 (2000) 2843-2855
82. Daubersies P., Thomas A.W., Millet P., Brahimi K., Langermans J.A., Ollomo B., et al. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nat Med 6 11 (2000) 1258-1263
83. Aidoo M., Lalvani A., Gilbert S.C., Hu J.T., Daubersies P., Hurt N., et al. Cytotoxic T-lymphocyte epitopes for HLA-B53 and other HLA types in the malaria vaccine candidate liver-stage antigen 3. Infect Immun 68 1 (2000) 227-232
84. Perlaza B.L., Zapata C., Valencia A.Z., Hurtado S., Quintero G., Sauzet J.P., et al. Immunogenicity and protective efficacy of Plasmodium falciparum liver-stage Ag-3 in Aotus lemurinus griseimembra monkeys. Eur J Immunol 33 5 (2003) 1321-1327
85. Patarroyo G., Franco L., Amador R., Murillo L.A., Rocha C.L., Rojas M., et al. Study of the safety and immunogenicity of the synthetic malaria SPf66 vaccine in children aged 1-14 years. Vaccine 10 3 (1992) 175-178
86. Alonso P.L., Smith T.A., Armstrong-Schellenberg J.R., Kitua A.Y., Masanja H., Hayes R., et al. Duration of protection and age-dependence of the effects of the SPf66 malaria vaccine in African children exposed to intense transmission of Plasmodium falciparum. J Infect Dis 174 2 (1996) 367-372
87. Alonso P.L., Smith T., Schellenberg J.R., Masanja H., Mwankusye S., Urassa H., et al. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 344 8931 (1994) 1175-1181
88. Beck H.P., Felger I., Huber W., Steiger S., Smith T., Weiss N., et al. Analysis of multiple Plasmodium falciparum infections in Tanzanian children during the phase III trial of the malaria vaccine SPf66. J Infect Dis 175 4 (1997) 921-926
89. Galindo C.M., Acosta C.J., Schellenberg D., Aponte J.J., Roca A., Oettli A., et al. Humoral immune responses during a malaria vaccine trial in Tanzanian infants. Parasite Immunol 22 9 (2000) 437-443
90. Rosas J.E., Pedraz J.L., Hernandez R.M., Gascon A.R., Igartua M., Guzman F., et al. Remarkably high antibody levels and protection against P. falciparum malaria in Aotus monkeys after a single immunisation of SPf66 encapsulated in PLGA microspheres. Vaccine 20 13/14 (2002) 1707-1710
91. Woehlbier U., Epp C., Kauth C.W., Lutz R., Long C.A., Coulibaly B., et al. Analysis of antibodies directed against merozoite surface protein 1 of the human malaria parasite Plasmodium falciparum. Infect Immun 74 2 (2006) 1313-1322
92. Genton B., Betuela I., Felger I., Al-Yaman F., Anders R.F., Saul A., et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis 185 6 (2002) 820-827
93. Fluck C., Smith T., Beck H.P., Irion A., Betuela I., Alpers M.P., et al. Strain-specific humoral response to a polymorphic malaria vaccine. Infect Immun 72 11 (2004) 6300-6305
94. Chitarra V., Holm I., Bentley G.A., Petres S., and Longacre S. The crystal structure of C-terminal merozoite surface protein 1 at 1.8 A resolution, a highly protective malaria vaccine candidate. Mol Cell 3 4 (1999) 457-464
95. Chang S.P., Case S.E., Gosnell W.L., Hashimoto A., Kramer K.J., Tam L.Q., et al. A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria. Infect Immun 64 1 (1996) 253-261
96. Daly T.M., and Long C.A. Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria. J Immunol 155 1 (1995) 236-243
97. Udhayakumar V., Anyona D., Kariuki S., Shi Y.P., Bloland P.B., Branch O.H., et al. Identification of T and B cell epitopes recognized by humans in the C-terminal 42-kDa domain of the Plasmodium falciparum merozoite surface protein (MSP)-1. J Immunol 154 11 (1995) 6022-6030
98. Sachdeva S., Mohmmed A., Dasaradhi P.V., Crabb B.S., Katyal A., Malhotra P., et al. Immunogenicity and protective efficacy of Escherichia coli expressed Plasmodium falciparum merozoite surface protein-1(42) using human compatible adjuvants. Vaccine 24 12 (2006) 2007-2016
99. Pichyangkul S., Gettayacamin M., Miller R.S., Lyon J.A., Angov E., Tongtawe P., et al. Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum. Vaccine 22 29-30 (2004) 3831-3840
100. Stoute J.A., Gombe J., Withers M.R., Siangla J., McKinney D., Onyango M., et al. Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya. Vaccine (2005)
101. Valderrama-Aguirre A., Quintero G., Gomez A., Castellanos A., Perez Y., Mendez F., et al. Antigenicity, immunogenicity, and protective efficacy of Plasmodium vivax MSP1 PV200l: a potential malaria vaccine subunit. Am J Trop Med Hyg 73 5 Suppl (2005) 16-24
102. Anders R.F., Crewther P.E., Edwards S., Margetts M., Matthew M.L., Pollock B., et al. Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi. Vaccine 16 2/3 (1998) 240-247
103. Kennedy M.C., Wang J., Zhang Y., Miles A.P., Chitsaz F., Saul A., et al. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect Immun 70 12 (2002) 6948-6960
104. Kocken C.H., Dubbeld M.A., Van Der Wel A., Pronk J.T., Waters A.P., Langermans J.A., et al. High-level expression of Plasmodium vivax apical membrane antigen 1 (AMA-1) in Pichia pastoris: strong immunogenicity in Macaca mulatta immunized with P. vivax AMA-1 and adjuvant SBAS2. Infect Immun 67 1 (1999) 43-49
105. Kocken C.H., Narum D.L., Massougbodji A., Ayivi B., Dubbeld M.A., van der Wel A., et al. Molecular characterisation of Plasmodium reichenowi apical membrane antigen-1 (AMA-1), comparison with P. falciparum AMA-1, and antibody-mediated inhibition of red cell invasion. Mol Biochem Parasitol 109 2 (2000) 147-156
106. Cortes A., Mellombo M., Mueller I., Benet A., Reeder J.C., and Anders R.F. Geographical structure of diversity and differences between symptomatic and asymptomatic infections for Plasmodium falciparum vaccine candidate AMA1. Infect Immun 71 3 (2003) 1416-1426
107. Polley S.D., and Conway D.J. Strong diversifying selection on domains of the Plasmodium falciparum apical membrane antigen 1 gene. Genetics 158 4 (2001) 1505-1512
108. Mitchell G.H., Thomas A.W., Margos G., Dluzewski A.R., and Bannister L.H. Apical membrane antigen 1, a major malaria vaccine candidate, mediates the close attachment of invasive merozoites to host red blood cells. Infect Immun 72 1 (2004) 154-158
109. Malkin E.M., Diemert D.J., McArthur J.H., Perreault J.R., Miles A.P., Giersing B.K., et al. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect Immun 73 6 (2005) 3677-3685
110. Saul A., Lawrence G., Allworth A., Elliott S., Anderson K., Rzepczyk C., et al. A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant. Vaccine 23 23 (2005) 3076-3083
111. Pan W., Huang D., Zhang Q., Qu L., Zhang D., Zhang X., et al. Fusion of two malaria vaccine candidate antigens enhances product yield, immunogenicity, and antibody-mediated inhibition of parasite growth in vitro. J Immunol 172 10 (2004) 6167-6174
112. Zhang D., and Pan W. Evaluation of three Pichia pastoris-expressed Plasmodium falciparum merozoite proteins as a combination vaccine against infection with blood-stage parasites. Infect Immun 73 10 (2005) 6530-6536
113. Bouharoun-Tayoun H., Attanath P., Sabchareon A., Chongsuphajaisiddhi T., and Druilhe P. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J Exp Med 172 6 (1990) 1633-1641
114. Bouharoun-Tayoun H., and Druilhe P. Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity. Infect Immun 60 4 (1992) 1473-1481
115. Bouharoun-Tayoun H., Oeuvray C., Lunel F., and Druilhe P. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med 182 2 (1995) 409-418
116. Oeuvray C., Bouharoun-Tayoun H., Gras-Masse H., Bottius E., Kaidoh T., Aikawa M., et al. Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood 84 5 (1994) 1594-1602
117. Audran R., Cachat M., Lurati F., Soe S., Leroy O., Corradin G., et al. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect Immun 73 12 (2005) 8017-8026
118. Druilhe P., Spertini F., Soesoe D., Corradin G., Mejia P., Singh S., et al. A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS Med 2 11 (2005) e344
119. Dodoo D., Theisen M., Kurtzhals J.A., Akanmori B.D., Koram K.A., Jepsen S., et al. Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria. J Infect Dis 181 3 (2000) 1202-1205
120. Theisen M., Soe S., Oeuvray C., Thomas A.W., Vuust J., Danielsen S., et al. The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro. Infect Immun 66 1 (1998) 11-17
121. Soe S., Theisen M., Roussilhon C., Aye K.S., and Druilhe P. Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein. Infect Immun 72 1 (2004) 247-252
122. Theisen M., Dodoo D., Toure-Balde A., Soe S., Corradin G., Koram K.K., et al. Selection of glutamate-rich protein long synthetic peptides for vaccine development: antigenicity and relationship with clinical protection and immunogenicity. Infect Immun 69 9 (2001) 5223-5229
123. Hermsen C.C., Verhage D.F., Telgt D.S., Teelen K., Bousema J.T., Roestenberg M., et al. Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial. Vaccine (2006)
124. Li J., Mitamura T., Fox B.A., Bzik D.J., and Horii T. Differential localization of processed fragments of Plasmodium falciparum serine repeat antigen and further processing of its N-terminal 47 kDa fragment. Parasitol Int 51 4 (2002) 343-352
125. Okech B.A., Nalunkuma A., Okello D., Pang X.L., Suzue K., Li J., et al. Natural human immunoglobulin G subclass responses to Plasmodium falciparum serine repeat antigen in Uganda. Am J Trop Med Hyg 65 6 (2001) 912-917
126. Okech B., Mujuzi G., Ogwal A., Shirai H., Horii T., and Egwang T.G. High titers of IgG antibodies against Plasmodium falciparum serine repeat antigen 5 (SERA5) are associated with protection against severe malaria in Ugandan children. Am J Trop Med Hyg 74 2 (2006) 191-197
127. Pang X.L., Mitamura T., and Horii T. Antibodies reactive with the N-terminal domain of Plasmodium falciparum serine repeat antigen inhibit cell proliferation by agglutinating merozoites and schizonts. Infect Immun 67 4 (1999) 1821-1827
128. Soe S., Singh S., Camus D., Horii T., and Druilhe P. Plasmodium falciparum serine repeat protein, a new target of monocyte-dependent antibody-mediated parasite killing. Infect Immun 70 12 (2002) 7182-7184
129. Inselburg J., Bathurst I.C., Kansopon J., Barchfeld G.L., Barr P.J., and Rossan R.N. Protective immunity induced in Aotus monkeys by a recombinant SERA protein of Plasmodium falciparum: adjuvant effects on induction of protective immunity. Infect Immun 61 5 (1993) 2041-2047
130. Inselburg J., Bathurst I.C., Kansopon J., Barr P.J., and Rossan R. Protective immunity induced in Aotus monkeys by a recombinant SERA protein of Plasmodium falciparum: further studies using SERA 1 and MF75.2 adjuvant. Infect Immun 61 5 (1993) 2048-2052
131. Marshall V.M., Silva A., Foley M., Cranmer S., Wang L., McColl D.J., et al. A second merozoite surface protein (MSP-4) of Plasmodium falciparum that contains an epidermal growth factor-like domain. Infect Immun 65 11 (1997) 4460-4467
132. Morgan W.D., Birdsall B., Frenkiel T.A., Gradwell M.G., Burghaus P.A., Syed S.E., et al. Solution structure of an EGF module pair from the Plasmodium falciparum merozoite surface protein 1. J Mol Biol 289 1 (1999) 113-122
133. Tolia N.H., Enemark E.J., Sim B.K., and Joshua-Tor L. Structural basis for the EBA-175 erythrocyte invasion pathway of the malaria parasite Plasmodium falciparum. Cell 122 2 (2005) 183-193
134. Jones T.R., Narum D.L., Gozalo A.S., Aguiar J., Fuhrmann S.R., Liang H., et al. Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen. J Infect Dis 183 2 (2001) 303-312
135. Arevalo-Herrera M., Castellanos A., Yazdani S.S., Shakri A.R., Chitnis C.E., Dominik R., et al. Immunogenicity and protective efficacy of recombinant vaccine based on the receptor-binding domain of the Plasmodium vivax Duffy binding protein in Aotus monkeys. Am J Trop Med Hyg 73 5 Suppl (2005) 25-31
136. Chen Q., Pettersson F., Vogt A.M., Schmidt B., Ahuja S., Liljestrom P., et al. Immunization with PfEMP1-DBL1alpha generates antibodies that disrupt rosettes and protect against the sequestration of Plasmodium falciparum-infected erythrocytes. Vaccine 22 21-22 (2004) 2701-2712
137. Smith J.D., and Deitsch K.W. Pregnancy-associated malaria and the prospects for syndrome-specific antimalaria vaccines. J Exp Med 200 9 (2004) 1093-1097
138. Ahuja S., Pettersson F., Moll K., Jonsson C., Wahlgren M., and Chen Q. Induction of cross-reactive immune responses to NTS-DBL-1alpha/x of PfEMP1 and in vivo protection on challenge with Plasmodium falciparum. Vaccine (2006)
139. Carter R., Mendis K.N., Miller L.H., Molineaux L., and Saul A. Malaria transmission-blocking vaccines-how can their development be supported?. Nat Med 6 3 (2000) 241-244
140. Hisaeda H., Stowers A.W., Tsuboi T., Collins W.E., Sattabongkot J.S., Suwanabun N., et al. Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes. Infect Immun 68 12 (2000) 6618-6623
141. Arakawa T., Komesu A., Otsuki H., Sattabongkot J., Udomsangpetch R., Matsumoto Y., et al. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum. Infect Immun 73 11 (2005) 7375-7380
142. Gozar M.M., Muratova O., Keister D.B., Kensil C.R., Price V.L., and Kaslow D.C. Plasmodium falciparum: immunogenicity of alum-adsorbed clinical-grade TBV25-28, a yeast-secreted malaria transmission-blocking vaccine candidate. Exp Parasitol 97 2 (2001) 61-69
143. Milek R.L., Stunnenberg H.G., and Konings R.N. Assembly and expression of a synthetic gene encoding the antigen Pfs48/45 of the human malaria parasite Plasmodium falciparum in yeast. Vaccine 18 14 (2000) 1402-1411
144. Malkin E.M., Durbin A.P., Diemert D.J., Sattabongkot J., Wu Y., Miura K., et al. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 23 24 (2005) 3131-3138
145. Collins W.E., Sullivan J.S., Williams A., Nace D., Williams T., Galland G.G., et al. Aotus nancymaae as a potential model for the testing of anti-sporozoite and liver stage vaccines against Plasmodium falciparum. Am J Trop Med Hyg 74 3 (2006) 422-424
146. Bustamante P.J., Woodruff D.C., Oh J., Keister D.B., Muratova O., and Williamson K.C. Differential ability of specific regions of Plasmodium falciparum sexual-stage antigen, Pfs230, to induce malaria transmission-blocking immunity. Parasite Immunol 22 8 (2000) 373-380
147. Pombo D.J., Lawrence G., Hirunpetcharat C., Rzepczyk C., Bryden M., Cloonan N., et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 360 9333 (2002) 610-617
148. Schofield L., Vivas L., Hackett F., Gerold P., Schwarz R.T., and Tachado S. Neutralizing monoclonal antibodies to glycosylphosphatidylinositol, the dominant TNF-alpha-inducing toxin of Plasmodium falciparum: prospects for the immunotherapy of severe malaria. Ann Trop Med Parasitol 87 6 (1993) 617-626
149. Schofield L., Hewitt M.C., Evans K., Siomos M.A., and Seeberger P.H. Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. Nature 418 6899 (2002) 785-789
150. Schofield L., and Mueller I. Clinical immunity to malaria. Curr Mol Med 6 2 (2006) 205-221
151. Perraut R., Marrama L., Diouf B., Sokhna C., Tall A., Nabeth P., et al. Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese village. J Infect Dis 191 2 (2005) 264-271
152. Pinder M., Sutherland C.J., Sisay-Joof F., Ismaili J., McCall M.B., Ord R., et al. Immunoglobulin G antibodies to merozoite surface antigens are associated with recovery from chloroquine-resistant Plasmodium falciparum in Gambian children. Infect Immun 74 5 (2006) 2887-2893
153. Persson K.E., Lee C.T., Marsh K., and Beeson J.G. Development and optimization of high-throughput methods to measure Plasmodium falciparum-specific growth inhibitory antibodies. J Clin Microbiol 44 5 (2006) 1665-1673
154. Good M.F., Xu H., Wykes M., and Engwerda C.R. Development and regulation of cell-mediated immune responses to the blood stages of malaria: implications for vaccine research. Annu Rev Immunol 23 (2005) 69-99
155. Krzych U., and Schwenk J. The dissection of CD8 T cells during liver-stage infection. Curr Top Microbiol Immunol 297 (2005) 1-24
156. Stephens R., and Langhorne J. Priming of CD4+ T cells and development of CD4+ T cell memory; lessons for malaria. Parasite Immunol 28 1/2 (2006) 25-30
157. Barrero C.A., Delgado G., Sierra A.Y., Silva Y., Parra-Lopez C., and Patarroyo M.A. Gamma interferon levels and antibody production induced by two PvMSP-1 recombinant polypeptides are associated with protective immunity against P. vivax in Aotus monkeys. Vaccine 23 31 (2005) 4048-4053
158. Kidgell C., Volkman S.K., Daily J., Borevitz J.O., Plouffe D., Zhou Y., et al. A systematic map of genetic variation in Plasmodium falciparum. PLoS Pathog 2 6 (2006) e57
159. Druilhe P., Hagan P., and Rook G.A. The importance of models of infection in the study of disease resistance. Trends Microbiol 10 10 Suppl (2002) S38-S46
160. Badell E., Oeuvray C., Moreno A., Soe S., van Rooijen N., Bouzidi A., et al. Human malaria in immunocompromised mice: an in vivo model to study defense mechanisms against Plasmodium falciparum. J Exp Med 192 11 (2000) 1653-1660
161. Stowers A.W., and Miller L.H. Are trials in New World monkeys on the critical path for blood-stage malaria vaccine development?. Trends Parasitol 17 9 (2001) 415-419
162. Heppner D.G., Cummings J.F., Ockenhouse C., Kester K.E., Lyon J.A., and Gordon D.M. New World monkey efficacy trials for malaria vaccine development: critical path or detour?. Trends Parasitol 17 9 (2001) 419-425
163. Rogers W.O., Atuguba F., Oduro A.R., Hodgson A., and Koram K.A. Clinical case definitions and malaria vaccine efficacy. J Infect Dis 193 3 (2006) 467-473
164. Struik S.S., and Riley E.M. Does malaria suffer from lack of memory?. Immunol Rev 201 (2004) 268-290
165. Bejon P., Kai O.K., Mwacharo J., Keating S., Lang T., Gilbert S.C., et al. Alternating vector immunizations encoding pre-erythrocytic malaria antigens enhance memory responses in a malaria endemic area. Eur J Immunol (2006)
166. Ballou W.R. Malaria vaccines in development. Expert Opin Emerg Drugs 10 3 (2005) 489-503